[
  {
    "ts": "2025-11-06T00:17:00+00:00",
    "headline": "Metsera Issues Statement in Response to Litigation Ruling",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer:",
    "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-001700501.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "ebd6390c-f1c4-3d4c-b2d8-489e9fb81f96",
      "content": {
        "id": "ebd6390c-f1c4-3d4c-b2d8-489e9fb81f96",
        "contentType": "STORY",
        "title": "Metsera Issues Statement in Response to Litigation Ruling",
        "description": "",
        "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer:",
        "pubDate": "2025-11-06T00:17:00Z",
        "displayTime": "2025-11-06T00:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/002971877c90ea768734c7a4e3df9643",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z7CW4Z46Q2d4F1vTH__5lQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/002971877c90ea768734c7a4e3df9643.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wzye6TKdasyqeLHD2xk0hA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/002971877c90ea768734c7a4e3df9643.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-001700501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-001700501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T09:10:00+00:00",
    "headline": "2 Dirt Cheap Stocks to Buy With $1,000 Right Now",
    "summary": "With big yields, these turnaround stocks look like they are attractively priced for those who can handle some uncertainty.",
    "url": "https://www.fool.com/investing/2025/11/06/2-dirt-cheap-stocks-to-buy-with-1000-right-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "5615feb5-6c3e-3a65-ad06-568c114dbebb",
      "content": {
        "id": "5615feb5-6c3e-3a65-ad06-568c114dbebb",
        "contentType": "STORY",
        "title": "2 Dirt Cheap Stocks to Buy With $1,000 Right Now",
        "description": "",
        "summary": "With big yields, these turnaround stocks look like they are attractively priced for those who can handle some uncertainty.",
        "pubDate": "2025-11-06T09:10:00Z",
        "displayTime": "2025-11-06T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/01fe851bf89a3eed00a2ec516398c647",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A hand drawing a scale showing price vs. value.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bjvWPQ8qSc5iNf1JBeK6ng--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/01fe851bf89a3eed00a2ec516398c647.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jsUqAMpZNKb_qReqgqwWEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/01fe851bf89a3eed00a2ec516398c647.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/06/2-dirt-cheap-stocks-to-buy-with-1000-right-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-dirt-cheap-stocks-buy-091000853.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "UPS"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T09:44:00+00:00",
    "headline": "Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting",
    "summary": "Pfizer just gave income investors four reasons to like its juicy dividend even more.",
    "url": "https://www.fool.com/investing/2025/11/06/why-pfizers-7-yielding-dividend-just-got-safer/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "b9044c1c-6543-3d72-a473-cf7442698a7c",
      "content": {
        "id": "b9044c1c-6543-3d72-a473-cf7442698a7c",
        "contentType": "STORY",
        "title": "Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting",
        "description": "",
        "summary": "Pfizer just gave income investors four reasons to like its juicy dividend even more.",
        "pubDate": "2025-11-06T09:44:00Z",
        "displayTime": "2025-11-06T09:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/a69ea8cbe042d77832ac0e4077716253",
          "originalWidth": 1024,
          "originalHeight": 652,
          "caption": "Pfizer logo.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9t2a..G1A6OOwqV71Gd20A--~B/aD02NTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/a69ea8cbe042d77832ac0e4077716253.cf.webp",
              "width": 1024,
              "height": 652,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9P_dp5vvUcyDyxq66umFA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a69ea8cbe042d77832ac0e4077716253.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/06/why-pfizers-7-yielding-dividend-just-got-safer/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizers-7-yielding-dividend-094400797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:11:57+00:00",
    "headline": "Pfizer Responds to Court Decision Rejecting Request to Temporary Halt Metsera-Novo Nordisk Deal",
    "summary": "Pfizer (PFE) said late Wednesday that it will continue to pursue its legal and antitrust claims agai",
    "url": "https://finance.yahoo.com/news/pfizer-responds-court-decision-rejecting-111157609.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "cc1189f9-664c-3faa-b9eb-48c30d89a751",
      "content": {
        "id": "cc1189f9-664c-3faa-b9eb-48c30d89a751",
        "contentType": "STORY",
        "title": "Pfizer Responds to Court Decision Rejecting Request to Temporary Halt Metsera-Novo Nordisk Deal",
        "description": "",
        "summary": "Pfizer (PFE) said late Wednesday that it will continue to pursue its legal and antitrust claims agai",
        "pubDate": "2025-11-06T11:11:57Z",
        "displayTime": "2025-11-06T11:11:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-responds-court-decision-rejecting-111157609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-responds-court-decision-rejecting-111157609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T10:07:39+00:00",
    "headline": "Stocks to Watch Thursday: Tesla, Robinhood, Metsera, Snap",
    "summary": "üîé Tesla (TSLA): The electric-vehicle maker will reveal if shareholders approved a $1 trillion pay package for CEO Elon Musk. They are also voting on whether Tesla should invest in Musk's xAI startup.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
      "content": {
        "id": "a1ff4ab9-5bf1-31bc-a536-a49e1309d556",
        "contentType": "STORY",
        "title": "Stocks to Watch Thursday: Tesla, Robinhood, Metsera, Snap",
        "description": "",
        "summary": "üîé Tesla (TSLA): The electric-vehicle maker will reveal if shareholders approved a $1 trillion pay package for CEO Elon Musk. They are also voting on whether Tesla should invest in Musk's xAI startup.",
        "pubDate": "2025-11-06T10:07:39Z",
        "displayTime": "2025-11-06T10:07:39Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a1ff4ab9-5bf1-31bc-a536-a49e1309d556/stocks-to-watch-thursday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zeifGFITRZDScQ8nFl9wgQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FeUttjJqxCTNJvBjDtiFGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7f21fc622a5019aaa9f920fde7426958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/stocks-to-watch-thursday-tesla-robinhood-qualcomm-snap-Fo5MAnWZYfK8mDDnkTyY?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "AMSYF"
            },
            {
              "symbol": "MT"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "DUOL"
            },
            {
              "symbol": "XAAI.PVT"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "QCOM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T13:09:23+00:00",
    "headline": "Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges",
    "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finance.yahoo.com/news/live/earnings-live-moderna-stock-pops-amid-cost-cutting-efforts-snap-stock-soars-duolingo-plunges-130923384.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "035a1404-14a9-4292-96b8-08cca27526ee",
      "content": {
        "id": "035a1404-14a9-4292-96b8-08cca27526ee",
        "contentType": "STORY",
        "title": "Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges",
        "description": "",
        "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
        "pubDate": "2025-11-06T13:09:23Z",
        "displayTime": "2025-11-06T13:24:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/9800e900-bb11-11f0-b7fd-92ce250976c9",
          "originalWidth": 3293,
          "originalHeight": 2195,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hb7SHXWVJnJ83O2OvrHuUg--~B/aD0yMTk1O3c9MzI5MzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/9800e900-bb11-11f0-b7fd-92ce250976c9.cf.webp",
              "width": 3293,
              "height": 2195,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yfFUaouzIWGqdWupA5VjWQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/9800e900-bb11-11f0-b7fd-92ce250976c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-moderna-stock-pops-amid-cost-cutting-efforts-snap-stock-soars-duolingo-plunges-130923384.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-moderna-stock-pops-amid-cost-cutting-efforts-snap-stock-soars-duolingo-plunges-130923384.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "DUOL"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "DASH"
            },
            {
              "symbol": "SMCI"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "UBER"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "ARM"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MCD"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "ABNB"
            },
            {
              "symbol": "CEG"
            },
            {
              "symbol": "MAR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:51:28+00:00",
    "headline": "AstraZeneca CEO bullish on record revenue numbers and US growth",
    "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
    "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
      "content": {
        "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
        "contentType": "VIDEO",
        "title": "AstraZeneca CEO bullish on record revenue numbers and US growth",
        "description": "<p>AstraZeneca's (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/AZN\">AZN</a>, <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.L\">AZN.L</a>, <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.ST\">AZN.ST</a>) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/JNJ\">JNJ</a>), Merck (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/MRK\">MRK</a>) and Pfizer (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>). For more live coverage of the markets, watch the full episode of <em>Market Sunrise</em> and visit<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/\"> Yahoo Finance</a>.</p>",
        "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
        "pubDate": "2025-11-06T12:51:28Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab",
          "originalWidth": 4787,
          "originalHeight": 2695,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YZigCM3MtAH584LADKiEmA--~B/aD0yNjk1O3c9NDc4NzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 4787,
              "height": 2695,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lb3cKjiVc_C_ZhL48TzyZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T13:01:00+00:00",
    "headline": "Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results",
    "summary": "Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-",
    "url": "https://finance.yahoo.com/news/sangamo-therapeutics-reports-recent-business-130100259.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "543d5646-8a38-3446-8b21-14bc790190d4",
      "content": {
        "id": "543d5646-8a38-3446-8b21-14bc790190d4",
        "contentType": "STORY",
        "title": "Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results",
        "description": "",
        "summary": "Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-",
        "pubDate": "2025-11-06T13:01:00Z",
        "displayTime": "2025-11-06T13:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/4c688b7fb4ce4aa527a538b9e9e8070b",
          "originalWidth": 3087,
          "originalHeight": 763,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yzeT2Jcm2HBwFKLnggPVYg--~B/aD03NjM7dz0zMDg3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/4c688b7fb4ce4aa527a538b9e9e8070b.cf.webp",
              "width": 3087,
              "height": 763,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m5bK_.5Yf1_ZofvSRERU2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4c688b7fb4ce4aa527a538b9e9e8070b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sangamo-therapeutics-reports-recent-business-130100259.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sangamo-therapeutics-reports-recent-business-130100259.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SGMO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:29:00+00:00",
    "headline": "Moderna Swings to a Loss. The Stock Jumps Anyway.",
    "summary": "Shares of  Moderna  rose sharply Thursday after the vaccine company reported better-than-expected quarterly results and narrowed its full-year guidance.  Moderna  posted a loss of 51 cents a share for the third quarter, down from a profit of 3 cents last year, but narrower than analysts‚Äô consensus calls for a loss of $2.12.  The company also said it now expects 2025 revenue of $1.6 billion to $2 billion, compared to a previous range of $1.5 billion to $2.2 billion.",
    "url": "https://www.barrons.com/articles/moderna-stock-earnings-preview-51975438?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "0b5bfd14-9904-3099-a0a9-8b9596ae958e",
      "content": {
        "id": "0b5bfd14-9904-3099-a0a9-8b9596ae958e",
        "contentType": "STORY",
        "title": "Moderna Swings to a Loss. The Stock Jumps Anyway.",
        "description": "",
        "summary": "Shares of  Moderna  rose sharply Thursday after the vaccine company reported better-than-expected quarterly results and narrowed its full-year guidance.  Moderna  posted a loss of 51 cents a share for the third quarter, down from a profit of 3 cents last year, but narrower than analysts‚Äô consensus calls for a loss of $2.12.  The company also said it now expects 2025 revenue of $1.6 billion to $2 billion, compared to a previous range of $1.5 billion to $2.2 billion.",
        "pubDate": "2025-11-06T12:29:00Z",
        "displayTime": "2025-11-06T12:29:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0b5bfd14-9904-3099-a0a9-8b9596ae958e/moderna-swings-to-a-loss-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/749fjdDNHOZZaiWMxvk7TQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rrBpMbNzvxDHGSjZc1Bgxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/e36505993ad3703ab9de7fbae2fb93fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/moderna-stock-earnings-preview-51975438?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:00:00+00:00",
    "headline": "Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases",
    "summary": "Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (‚ÄúAccipiter Bio‚Äù), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with",
    "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "792a147e-6e7a-3d78-b07e-d02a2f3dc5c7",
      "content": {
        "id": "792a147e-6e7a-3d78-b07e-d02a2f3dc5c7",
        "contentType": "STORY",
        "title": "Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases",
        "description": "",
        "summary": "Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (‚ÄúAccipiter Bio‚Äù), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with",
        "pubDate": "2025-11-06T12:00:00Z",
        "displayTime": "2025-11-06T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c",
          "originalWidth": 2404,
          "originalHeight": 669,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TczC315ovJ4ZaOckt0ONjA--~B/aD02Njk7dz0yNDA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c.cf.webp",
              "width": 2404,
              "height": 669,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nwHooGBhqjyBZ5rEFHWJnA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/30bed581fbd1bf65f619bc3449ca564c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/accipiter-biosciences-emerges-stealth-12-120000362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:00:00+00:00",
    "headline": "C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
    "summary": "Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 ¬µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomid",
    "url": "https://finance.yahoo.com/news/c4-therapeutics-reports-third-quarter-120000313.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c4685d8c-ce4c-3909-bc17-3f1bec31a76a",
      "content": {
        "id": "c4685d8c-ce4c-3909-bc17-3f1bec31a76a",
        "contentType": "STORY",
        "title": "C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
        "description": "",
        "summary": "Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 ¬µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomid",
        "pubDate": "2025-11-06T12:00:00Z",
        "displayTime": "2025-11-06T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d0dfe2d0cea5566d521085e071900a8d",
          "originalWidth": 1002,
          "originalHeight": 150,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B0S9UMNaqszRoii9p9Qo9A--~B/aD0xNTA7dz0xMDAyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d0dfe2d0cea5566d521085e071900a8d.cf.webp",
              "width": 1002,
              "height": 150,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G8SV39wV81QSgpSKqshtEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d0dfe2d0cea5566d521085e071900a8d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/c4-therapeutics-reports-third-quarter-120000313.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/c4-therapeutics-reports-third-quarter-120000313.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CCCC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:46:47+00:00",
    "headline": "Pfizer Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions",
    "summary": "The third-quarter results for Pfizer Inc. ( NYSE:PFE ) were released last week, making it a good time to revisit its...",
    "url": "https://finance.yahoo.com/news/pfizer-inc-just-beat-analyst-114647391.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4d9d5a00-aa2c-381e-84fb-a038998d0f67",
      "content": {
        "id": "4d9d5a00-aa2c-381e-84fb-a038998d0f67",
        "contentType": "STORY",
        "title": "Pfizer Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions",
        "description": "",
        "summary": "The third-quarter results for Pfizer Inc. ( NYSE:PFE ) were released last week, making it a good time to revisit its...",
        "pubDate": "2025-11-06T11:46:47Z",
        "displayTime": "2025-11-06T11:46:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-just-beat-analyst-114647391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-just-beat-analyst-114647391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T08:00:00+00:00",
    "headline": "Why Pfizer and Novo are duking it out over weight loss startup Metsera",
    "summary": "A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena‚Äôs high stakes.",
    "url": "https://www.pharmavoice.com/news/pfizer-novo-nordisk-metsera-weight-loss-deal-billions/804804/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "f6f639ff-4fde-364d-abd6-7fc48b7ca648",
      "content": {
        "id": "f6f639ff-4fde-364d-abd6-7fc48b7ca648",
        "contentType": "STORY",
        "title": "Why Pfizer and Novo are duking it out over weight loss startup Metsera",
        "description": "",
        "summary": "A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena‚Äôs high stakes.",
        "pubDate": "2025-11-06T08:00:00Z",
        "displayTime": "2025-11-06T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/513c8dc3abab8ce2dd0a04c236cee51c",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.YZIZjg8LJrU3SxCnuMBNA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/513c8dc3abab8ce2dd0a04c236cee51c.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F.bI.0tojD92WU2Ik17KtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/513c8dc3abab8ce2dd0a04c236cee51c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/pfizer-novo-nordisk-metsera-weight-loss-deal-billions/804804/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-pfizer-novo-duking-over-080000979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]